Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Tofacitinib helped a woman regrow hair with no major side effects.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

Tofacitinib treatment is used for teenagers with alopecia areata.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

A patient with complete hair loss regrew all her hair using tofacitinib.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

A man developed skin issues from cancer medication, which improved with specific treatments.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

JAK inhibitors are effective for long-term management of alopecia areata.